Story thread · 10 reports / 6 sources

Gilead Slumps As Long-Term Uncertainty Clouds Massive HIV Beat

finance.yahoo.com · 6d

Gilead Slumps As Long-Term Uncertainty Clouds Massive HIV Beat

How the coverage leans

Across 6 sources · syndicated copies counted once

First report: Could Gilead Sciences (GILD) Have a Major HIV Growth Engine in Yeztugo? — finance.yahoo.com, 7d

The coverage

Gilead Sciences in charts: Q2 base sales jump 10% on HIV, oncology growth despite Veklury drop
seekingalpha.com · 6d
Gilead’s Yeztugo beats forecasts as HIV PrEP franchise exceeds $1B
endpts.com · 6d

The conversation · 0

Sign in to join the conversation.

No comments yet — start the thread.